×
Guidebook
Details
Download Guide
Account
Log In
Create an Account
ASCPT 2015 Annual Meeting
Mar 3, 2015 - Mar 7, 2015
New Orleans, LA
General Info
Schedule
Speakers
Exhibitors
Poster Abstracts
Oral Abstracts
AM Survey
Maps
To-do
My Schedule
Inbox
LinkedIn
Facebook
Asparagus Project
Registrants
Back
Poster Session II
Date & Time
Mar 6th
at
4:30 PM
until
6:30 PM
Track
Poster
Location
Elite Hall
Rating
( votes)
Poster Abstracts
PII-119
ASSESSMENT OF CLINICAL RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) BETWEEN PF-05280586, A PROPOSED BIOSIMILAR TO RITUXIMAB AND TWO RITUXIMAB PRODUCTS.
PII-118
ASSESSMENT OF DRUG INTERACTION POTENTIAL BY NIVOLUMAB USING CYTOKINE MODULATION DATA.
PII-117
ABSENCE OF QT PROLONGATION (QTP) EFFECT BY NIVOLUMAB (NIVO) OR IPILIMUMAB (IPI) IN SUBJECTS WITH SOLID TUMORS.
PII-116
PHARMACOKINETICS AND PHARMACODYNAMICS OF BENRALIZUMAB IN SUBJECTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
PII-115
IMMUNOGENICITY OF NIVOLUMAB AND ITS IMPACT ON PHARMACOKINETICS (PK) AND SAFETY IN SUBJECTS WITH METASTATIC SOLID TUMORS.
PII-114
ELUCIDATION OF THE MECHANISM OF THERAPEUTIC PROTEIN-DRUG INTERACTION (TPDI) BETWEEN METHOTREXATE (MTX) AND AN ANTI-TNFα MONOCLONAL ANTIBODY (MAB), GOLIMUMAB.
PII-113
PHARMACOKINETICS (PK) OF TWO 6-MERCAPTOPURINE (6-MP) LIQUID FORMULATIONS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL).
PII-112
PHARMACOKINETICS OF SINGLE DOSE ESCITALOPRAM IN THE HEALTHY ELDERLY COMPARED WITH THE YOUNG.
PII-111
PHARMACOKINETICS OF ELAGOLIX, A NOVEL ORAL GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONIST, ADMINISTERED TO FEMALE SUBJECTS WITH RENAL IMPAIRMENT.
PII-110
PHARMACOKINETICS OF ELAGOLIX, A NOVEL ORAL GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONIST ADMINISTERED TO FEMALE SUBJECTS WITH HEPATIC IMPAIRMENT.
PII-109
THE EFFECT OF HEPATIC IMPAIRMENT (HI) OR HCV INFECTION ON THE PHARMACOKINETICS (PK) OF BUPRENORPHINE AND NALOXONE.
PII-108
AGE-DEPENDENT CHANGES IN CYP3A METABOLIC CAPACITY DETERMINE SIROLIMUS CLEARANCE IN PEDIATRIC PATIENTS.
PII-107
ANALYSIS OF THE EFFECT OF VARIOUS DEGREES OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS OF NONRENALLY ELIMINATED DRUGS.
PII-106
STEADY-STATE PHARMACOKINETICS OF GSK1278863 AND METABOLITES IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL FUNCTION.
PII-105
THE PHARMACOGENETICS OF CODEINE PAIN RELIEF IN THE POSTPARTUM PERIOD.
PII-104
ASSOCIATION OF MEGALIN GENETIC POLYMORPHISMS WITH ACUTE KIDNEY INJURY (AKI) IN AMINOGLYCOSIDE (AG)-TREATED NEWBORNS.
PII-103
EVALUATION OF THE QTC PROLONGATION POTENTIAL OF TWO NEUROPSYCHIATRIC DRUGS QUETIAPINE AND ESCITALOPRAM IN HEALTHY VOLUNTEERS.
PII-102
THE CATASTROPHIC FIRST-IN-HUMAN TGN1412 TRIAL; A SYSTEMATIC REVIEW OF PUBLICATION PATTERNS AND LESSONS LEARNED SINCE THE 2006 INCIDENT.
PII-101
AZITHROMYCIN IS NOT ASSOCIATED WITH QT PROLONGATION IN HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA.
PII-100
OPPOSITE EFFECTS OF ST. JOHN’S WORT AND RIFAMPIN ON GLUCOSE METABOLISM IN HEALTHY VOLUNTEERS.
PII-099
A CONCENTRATION-QTC ANALYSIS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER RECEIVING CRIZOTINIB: ACCOUNTING FOR BIAS IN CORRECTION METHODS.
PII-098
PHARMACOKINETICS (PK) AND SAFETY OF ARGININE VASOPRESSIN TYPE-1B (V1B) RECEPTOR ANTAGONIST ABT-436 IN HEALTHY VOLUNTEERS FOLLOWING MULTIPLE DOSES.
PII-097
PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF HUMAN ANTI-FGF23 ANTIBODY (KRN23) AND SERUM PHOSPHORUS IN ADULTS WITH X-LINKED HYPOPHOSPHATEMIA.
PII-096
PHARMACOKINETICS AND SAFETY OF SINGLE ASCENDING DOSES, FOOD EFFECT AND KETOCONAZOLE (KTZ) INTERACTION OF ARGININE VASOPRESSIN TYPE-1B (V1B) RECEPTOR ANTAGONIST ABT-436.
PII-095
POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ASSESSMENT OF ANTI-CD79B ANTIBODY DRUG CONJUGATE IN PATIENTS: INTERIM ANALYSIS RESULTS.
PII-094
A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR PREDICTION OF PLASMA AND LUNG CONCENTRATIONS AFTER ADMINISTRATION OF CEFTAZIDIME.
PII-093
ATAZANAVIR ABSORPTION IN HEALTHY VOLUNTEERS WITH PHARMACOLOGICALLY-INDUCED HYPOCHLORHYDRIA USING BETAINE HCL.
PII-092
A PHASE I, OPEN-LABEL STUDY TO DETERMINE THE EFFECT OF SYM-1219 ON THE PHARMACOKINETICS OF ETHINYL ESTRADIOL (EE2) AND NORETHINDRONE (NET) IN HEALTHY FEMALE VOLUNTEERS.
PII-091
POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF ECULIZUMAB TO SUPPORT PHASE III DOSING REGIMEN IN PATIENTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS.
PII-090
POTENTIAL PRASUGREL DRUG INTERACTIONS BASED ON INHIBITION OF CARBOXYLESTERASE-2.
PII-089
PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) ANALYSES OF ARGININE VASOPRESSIN TYPE-1B (V1B) RECEPTOR ANTAGONIST EFFECT ON CORTISOL.
PII-088
EFFECT OF RENAL AND HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF CABOZANTINIB (CABO).
PII-087
POPULATION PHARMACOKINETICS OF BELIMUMAB IN HEALTHY AMERICAN AND JAPANESE SUBJECTS FOLLOWING SUBCUTANEOUS ADMINISTRATION.
PII-086
POPULATION PHARMACOKINETICS OF TD-9855, A NOREPINEPHRINE AND SEROTONIN REUPTAKE INHIBITOR (NSRI), IN HEALTHY SUBJECTS AND PATIENTS WITH ADULT ADHD OR FIBROMYALGIA.
PII-085
PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA PATIENTS AGED 60 AND ABOVE.
PII-084
EFFECT OF INTRINSIC AND EXTRINSIC FACTORS ON PHARMACOKINETICS OF IDELALISIB, A NOVEL PI3Kδ INHIBITOR, IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES.
PII-083
PHARMACOKINETIC COMPARISON OF COMPOUND K AFTER ORAL ADMINISTRATION OF FERMENTED RED GINSENG EXTRACTS, RED GINSENG EXTRACTS AND GINSENG EXTRACTS IN HEALTHY SUBJECTS.
PII-082
PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY, AND SAFETY OF BMS-938790 IN HEALTHY SUBJECTS.
PII-081
EFFECT OF ACID REDUCING AGENTS ON THE PHARMACOKINETICS OF IDELALISIB, A NOVEL PI3Kδ INHIBITOR, IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES.
PII-080
PHARMACOKINETIC, PHARMACODYNAMIC AND TOLERBILITY PROFILES OF CKD-11101, A BIOSIMILAR TO NESP®, AFTER A SINGLE INTRAVENOUS ADMINISTRATION IN HEALTHY VOLUNTEERS.
PII-079
IMMUNOGENICITY AND TOLERABILITY OF NOVEL HUMAN PAPILLOMAVIRUS-16/18 VACCINE IN HEALTHY MALE VOLUNTEERS.
PII-078
POPULATION PHARMACOKINETICS OF KRN23, A HUMAN ANTI-FGF23 ANTIBODY DEVELOPED FOR THE TREATMENT OF ADULTS WITH X-LINKED HYPOPHOSPHATEMIA.
PII-077
PHARMACOKINETIC, PHARMACODYNAMIC AND TOLERBILITY PROFILES OF CKD-11101, A BIOSIMILAR TO NESP<sup>®</sup>, AFTER A SINGLE SUBCUTANEOUS ADMINISTRATION IN HEALTHY VOLUNTEERS.
PII-076
POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING FOR AN ANTISENSE OLIGONUCLEOTIDE (ISIS-FXIRx), TARGETING FACTOR XI, IN HEALTHY SUBJECTS.
PII-075
ASSESSMENT OF ABSOLUTE BIOAVAILABILITY AND MASS BALANCE OF THE PI3K INHIBITOR TASELISIB (GDC-0032) IN HEALTHY SUBJECTS.
PII-074
PHARMACOKINETICS (PK) OF SUBCUTANEOUS (SC) AZACITIDINE (AZA) IN CHINESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) FROM A PHASE II, OPEN-LABEL STUDY.
PII-073
ASSESSMENT OF PHARMACOKINETIC INTERACTION BETWEEN THE PI3K INHIBITOR TASELISIB (GDC-0032) AND A STRONG CYP3A4 INDUCER OR INHIBITOR.
PII-072
SERUM HEMOGLOBIN IS A PREDICTOR OF TACROLIMUS WHOLE BLOOD CONCENTRATION IN HEMATOPOEITIC STEM CELL TRANSPLANT PATIENTS.
PII-071
APPLICATION OF PBPK AND BAYESIAN MODELING FOR PREDICTION OF THE LIKELIHOOD OF INDIVIDUAL PATIENTS EXPERIENCING SERIOUS ADVERSE REACTIONS TO A STANDARD DOSE OF EFAVIRENZ.
PII-070
BIOEQUIVALENCE AND PHARMACOKINETIC EVALUATION OF TWO FORMULATIONS OF ULTRACET® ER TABLET.
PII-069
CLINICAL PHARMACOLOGY STUDY OF TELAPREVIR IN HEALTHY KOREAN VOLUNTEERS AFTER SINGLE AND MULTIPLE ORAL ADMINISTRATIONS.
PII-068
POPULATION PHARMACOKINETIC-PHARMACODYNAMIC (PKPD) MODELING OF AMG 747, A GLYCINE TRANSPORTER TYPE 1 (GLYT 1) INHIBITOR, IN HEALTHY SUBJECTS.
PII-067
BIOEQUIVALENCE OF ROSUVASTATIN/EZETIMIBE COMBINATION TABLETS AND CO-ADMINISTRATION OF ROSUVASTATIN AND EZETIMIBE IN HEALTHY KOREAN SUBJECTS.
PII-066
THE PAN-PHOSPHOINOSITIDE-3 KINASE INHIBITOR PICTILISIB (GDC-0941), AN <i>IN VITRO</i> CYP2C8 INHIBITOR, DOES NOT IMPACT THE PHARMACOKINETICS OF PACLITAXEL, A CYP2C8 SUBSTRATE.
PII-065
PHARMACOMETRICS ENABLED RATIONAL DETERMINATION OF OPTIMAL DOSING REGIMEN FOR BENRALIZUMAB PIVOTAL STUDIES IN ADULTS AND ADOLESCENTS WITH ASTHMA.
PII-064
CLINICAL PHARMACOKINETICS STUDIES AIMED AT EFFECTIVELY AND EFFICIENTLY MONITORING THERAPEUTIC DRUG MONITORING METHOD OF MYCOPHENOLIC ACID IN RENAL TRANSPLANT RECIPIENTS.
PII-063
CONCENTRATION-QTc MODELING IN FIRST-IN-HUMAN STUDY TO ASSESS THE EFFECT OF THE INVESTIGATIONAL DRUG GS-4997 ON CARDIAC REPOLARIZATION.
PII-062
DRUG-DRUG INTERACTIONS OF OMEPRAZOLE WITH THE HCV DIRECT ACTING ANTIVIRAL (DAA) COMBINATION OF ABT-450/R, OMBITASVIR AND DASABUVIR.
PII-061
POPULATION PHARMACOKINETICS OF CIPROFLOXACIN AND DOSING RECOMMENDATION IN NEONATES AND INFANTS LESS THAN 3 MONTHS OF AGE.
PII-060
EVALUATION OF THE TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORALLY ADMINISTERED DWP05195, A NEW TRPV1 ANTAGONIST IN HEALTHY ADULT MALE VOLUNTEERS.
PII-059
POPULATION PHARMACOKINETIC ANALYSIS OF SUMATRIPTAN IN HEALTHY KOREAN MALE SUBJECTS.
PII-058
EFFECT OF NEOMYCIN (N) ON THE PHARMACOKINETICS (PK) OF REGORAFENIB (REG).
PII-057
ASSESSING SYNERGY OF DRUG AGONISTS USING A SURFACE RESPONSE ANALYSIS IN R.
PII-056
MODELING AND SIMULATION-GUIDED RATIONAL DRUG DISCOVERY AND DEVELOPMENT: A CASE STUDY OF MAVRILIMUMAB.
PII-055
INFORMATIVE DROPOUT MODELING AND EXPOSURE-RESPONSE ANALYSIS FOR MAVRILIMUMAB PHASE IIB STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS.
PII-054
A MULTIPLE-DOSE STUDY OF BLOCKADE OF OPIOID SUBJECTIVE EFFECTS BY SUBCUTANEOUS INJECTIONS OF DEPOT BUPRENORPHINE IN SUBJECTS WITH OPIOID USE DISORDER.
PII-053
PHARMACOKINETICS AND TOLERABILITY OF IDP-73152 MESYLATE AFTER A SINGLE ORAL ADMINISTRATION UNDER FASTING AND FED CONDITIONS IN HEALTHY VOLUNTEERS.
PII-052
APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO BOSUTINIB PHARMACOKINETICS: PREDICTION OF DRUG-DISEASE INTERACTION IN ORGAN DYSFUNCTION PATIENTS.
PII-051
APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO BOSUTINIB PHARMACOKINETICS: PREDICTION OF DRUG-DRUG INTERACTIONS AS CYP3A SUBSTRATE.
PII-050
EFFECTS OF ETHANOL ON ASPIRIN HYDROLYSIS BY CARBOXYLESTERASE-2 IN HUMANS.
PII-049
A TARGET MEDIATED DRUG DISPOSITION (TMDD) DOSE OPTIMIZATION OF RG7116, A HER3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS EXPRESSING HER3.
PII-048
POPULATION PHARMACODYNAMIC MODELING OF LANREOTIDE AUTOGEL IN JAPANESE ACROMEGALIC PATIENTS.
PII-047
SITE OF INJECTION DOES NOT AFFECT DULAGLUTIDE PHARMACOKINETICS.
PII-046
NO DOSE ADJUSTMENT IS NEEDED WHEN COADMINISTERING DULAGLUTIDE WITH A COMBINATION ORAL CONTRACEPTIVE.
PII-045
SAFETY, TOLERABILITY AND PHARMACOKINETIC CHARACTERISITCS OF VVZ-149 INJECTION IN HEALTHY SUBJECTS.
PII-044
DRUG INTERACTION POTENTIAL OF EMTRICITABINE (F; FTC)/TENOFOVIR (TFV) ALAFENAMIDE (TAF) (F/TAF) FIXED DOSE COMBINATION AND COBICISTAT (COBI)-BOOSTED DARUNAVIR (DRV).
PII-043
EFFECT OF FOOD ON THE PHARMACOKINETICS OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR CERITINIB IN HEALTHY SUBJECTS.
PII-042
A PHASE I STUDY TO DETERMINE THE SINGLE DOSE SAFETY AND PHARMACOKINETICS OF SYM-1219 (SECNIDAZOLE) IN HEALTHY FEMALE VOLUNTEERS.
PII-041
INVESTIGATION INTO THE INTERCHANGEABILITY OF GENERIC FORMULATIONS USING A RANDOM SELECTION OF MEDICINES AND IMMUNOSUPPRESSANTS.
PII-040
NOVEL METHODOLOGY FOR ESTIMATING THE TREATMENT EFFECT IN PRESENCE OF HIGHLY VARIABLE PLACEBO RESPONSE.
PII-039
A TWO-WEEK COURSE OF HIGH-DOSE INTEGRASE INHIBITORS DOES NOT LEAD TO NEPHROTOXICITY IN MICE.
PII-038
GENOME-WIDE ASSOCIATION STUDY IDENTIFIES NOVEL SUSCEPTIBILITY LOCI FOR VENOUS THROMBOEMBOLISM IN AFRICAN AMERICANS.
PII-037
SEARCHING FOR OPTIMAL THERAPY OF THE AMYLOID PATHOLOGY USING MECHANISM-BASED MODEL.
PII-036
ALTERED VITAMIN A HOMEOSTASIS IN CHRONIC KIDNEY DISEASE.
PII-035
DIFFERENCES IN MYCOPHENOLIC ACID AND METABOLITE, MYCOPHENOLIC ACID GLUCURONIDE EXPOSURES BETWEEN CALCINEURIN INHIBITOR REGIMENS POST-RENAL TRANSPLANT.
PII-034
EVOLOCUMAB PHARMACOKINETICS AND ITS EFFECTS ON LDL-C AND PCSK9 LOWERING IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT.
PII-033
POPULATION PHARMACOKINETICS OF BEVACIZUMAB: ANALYSIS OF INDIVIDUAL DATA FROM 1,792 PATIENTS WITH SOLID TUMORS FROM 15 STUDIES.
PII-032
A MODEL RELATING OVERALL SURVIVAL RELATED TO TUMOR GROWTH INHIBITION IN RENAL CELL CARCINOMA PATIENTS TREATED WITH SUNITINIB, AXITINIB OR TEMSIROLIMUS.
PII-031
A PHARMACOKINETIC AND PHARMACOGENETIC STUDY OF ALISERTIB COMBINED WITH IRINOTECAN AND TEMOZOLOMIDE IN CHILDREN AND ADOLESCENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA.
PII-030
TARGETING TUMOR-ASSOCIATED HYPOXIA TO OVERCOME CHEMORESISTANCE IN PANCREATIC DUCTAL ADENOCARCINOMA (PDA).
PII-029
POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF VORINOSTAT IN PATIENTS WITH ADVANCED SOLID TUMORS WITH VARYING DEGREES OF HEPATIC FUNCTION.
PII-028
POPULATION PHARMACOKINETIC (PPK) MODELING OF AXITINIB IN PATIENTS WITH METASTATIC OR UNRESECTABLE LOCALLY ADVANCED THYROID CANCER.
PII-027
ASSESSMENT OF THE POTENTIAL FOR DRUG-DRUG INTERACTIONS BETWEEN TRASTUZUMAB EMTANSINE (T-DM1) AND CYP3A INHIBITORS OR INDUCERS AND THE IMPACT ON ITS PK AND SAFETY.
PII-026
GENOME-WIDE ASSOCIATION STUDY TO IDENTIFY SUSCEPTIBILITY LOCI ASSOCIATED WITH HEMORRHAGIC COMPLICATIONS AMONG AFRICAN AMERICAN PATIENTS ON STABLE WARFARIN DOSE.
PII-025
INTENSIVE STATINS EXHIBIT VARIABLE PARADOXICAL EFFECTS WHEN COMBINED WITH FIBRATES IN A MODEL OF CARDIOVASCULAR DISEASE.
PII-024
P-MAP: NETWORK BIOLOGY APPLIED TO DETERMINE CELLULAR SENSITIVITY OF DRUG RESPONSE IN TRIPLE NEGATIVE BREAST CANCER CELL LINES.
PII-023
INTERINDIVIDUAL VARIABILITY IN CYP2D6 ACTIVITY IN HUMAN LIVER MICROSOMES TO CHARACTERIZE RARE GENETIC VARIATION.
PII-022
ABC TRANSPORTER POLYMORPHISMS ARE ASSOCIATED WITH IRINOTECAN EXPOSURE AND NEUTROPENIA.
PII-021
RIFAMPIN REGULATION OF DRUG TRANSPORTERS AND THE ROLE OF MICRORNA IN HUMAN HEPATOCYTES.
PII-020
RHEIN ELICITS <i>IN VITRO</i> CYTOTOXICITY IN PRIMARY HUMAN LIVER L-02 (HL-7702) CELLS BY INDUCING APOPTOSIS VIA MITOCHONDRIA-MEDIATED PATHWAY.
PII-019
PHARMACOGENOMICS OF MITHRAMYCIN-INDUCED HEPTATOTOXICITY.
PII-018
METABOLISM OF OLANZAPINE IN HUMAN HEART MICROSOMES.
PII-017
CYP2D6 GENE COPY NUMBER VARIATION (CNV): HOW ACCURATE IS THE AFFYMETRIX CytoScan HD?.
PII-016
THE EFFECT OF CIGARETTE SMOKING ON THE PLASMA AND URINE EICOSANOID METABOLIC PROFILE IN A HEALTHY MALE POPULATION.
PII-015
ILOPERIDONE METABOLISM IN HUMAN HEART.
PII-014
THE EFFECT OF INTRACELLULAR METHADONE ON HERG CURRENT IS MODULATED BY THE COEXPRESSION OF THE CYP450 ISOZYME 2B6.
PII-013
IDENTIFICATION AND FUNCTIONAL STUDIES OF CYP4V2 VARIANTS AMONG KOREAN POPULATION.
PII-012
STATIN INHIBITION OF LACTIC ACID TRANSPORT IN HUMAN SKELETAL MUSCLE.
PII-011
EXPLORATORY HUMAN ABUSE POTENTIAL ASSESSMENT OF CENTANAFADINE, A NOVEL TRIPLE REUPTAKE INHIBITOR.
PII-010
PHARMACOKINETIC INTERACTION BETWEEN ROSUVASTATIN AND FENOFIBRATE IN HEALTHY VOLUNTEERS.
PII-009
INTRA-ARTERIAL MICRODOSING (IAM), A NOVEL DRUG DEVELOPMENT APPROACH, PROOF OF CONCEPT IN RATS.
PII-008
PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL PREDICTIONS OF CYP MEDIATED DDIS: POTENTIAL INTERACTIONS BETWEEN ICA-105665 AND CYP ENZYME INDUCERS.
PII-007
PRECLINICAL EFFICACY OF T-LAK CELL-ORIGINATED PROTEIN KINASE INHIBITOR IN FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA.
PII-006
INTERACTIVE GENOTYPE-BASED DOSING GUIDELINES.
PII-005
EFFECTS OF CC-220, AN ORAL IMMUNOMODULATOR, ON IMMUNE RESPONSES.
PII-004
GENOME WIDE ASSOCIATION ANALYSIS WITH AMINE METABOLITES REVEALS NOVEL LOCI IMPACTING HUMAN METABOLOMIC PROFILES.
PII-003
ENDOGENOUS BILE ACIDS ARE POTENTIAL BIOMARKERS FOR OATP1B3 ACTIVITY.
PII-002
<i>IN VITRO</i>-<i>IN VIVO</i> CORRELATION (IVIVC) OF DRUG INDUCED INHIBITION OF CREATININE TUBULAR SECRETION USING MDCK CELLS EXPRESSING OCT2/OAT2/OCT3/MATE1/MATE2K TRANSPORTERS.
PII-001
THE COMPLEXITY AND DYNAMICS OF TUMOR RESPONSE TO VORINOSTAT CAN BE ELUCIDATED BY INTEGRATING MULTIPLE LARGE HIGH-THROUGHPUT DATASETS.
You can only register for sessions within the App.
Download the app here.